Granocyte (Lenograstim)

Granocyte is indicated for clinical situations where neutrophil recovery is needed after myelosuppressive treatments.

• To reduce the duration of neutropenia following chemotherapy in cancer patients.
• To support neutrophil counts after autologous or allogeneic stem cell transplantation.
• To mobilize peripheral blood progenitor cells for collection prior to transplantation.
• To treat severe chronic neutropenia in patients with congenital or acquired disorders.
• To facilitate faster hematologic recovery in patients receiving high‑dose radiation therapy.

The safety profile of lenograstim includes a range of observed adverse events that vary in frequency and severity.

Common

• Bone pain, especially in the lower back or hips.
• Mild fever or chills.
• Injection site reactions such as redness, swelling, or itching.
• Fatigue or general weakness.
• Elevated liver enzymes.

Serious

• Splenic rupture, a rare but potentially life‑threatening condition.
• Acute respiratory distress syndrome (ARDS) or severe pulmonary edema.
• Allergic reactions including anaphylaxis, characterized by rash, swelling, and difficulty breathing.
• Thrombotic events such as deep‑vein thrombosis.
• Severe hypotension or shock related to hypersensitivity.

When prescribing Granocyte, clinicians should evaluate patient history and monitor specific parameters to minimize risk.

• Assess baseline neutrophil counts and overall bone marrow function before initiating therapy.
• Use caution in patients with a history of splenic enlargement or trauma.
• Monitor for signs of hypersensitivity during and after each injection.
• Adjust dose or discontinue if persistent fever or unexplained infections develop.
• Avoid use in patients with active malignant disease that may be stimulated by growth factors.
• Consider renal or hepatic impairment when determining dosing intervals.

Lenograstim may interact with other medications or clinical conditions, influencing its efficacy or safety.

Avoid

• Concurrent use of chemotherapy agents that cause profound myelosuppression without appropriate timing adjustments.
• Co‑administration with other hematopoietic growth factors unless clinically justified.
• Use with investigational agents that lack safety data in combination with G‑CSF.

Use with caution

• Anticoagulants, as rapid neutrophil recovery can affect bleeding risk.
• Corticosteroids, which may mask fever or infection signs.
• Immunosuppressive biologics that could alter immune response to G‑CSF.